Paper Details

  1. Home
  2. Paper Details

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.

Author: DennyLynette, DescampsDominique, DobbelaereKurt, DurandChristelle, GordonChivaugn, HendricksBronwyn, HervéCaroline, HezarehMarjan, ThomasFlorence

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The HPV-16/18 AS04-adjuvanted vaccine was immunogenic and well-tolerated in women with HIV infection in a study conducted in South Africa. All vaccinated women were seropositive for both HPV-16 and HPV-18 after the second vaccine dose and remained seropositive at month 12. The vaccine induced sustained anti-HPV-16/18 CD4⁺ T-cell responses in both HIV-positive and HIV-negative women. CD4⁺ T-cell count, HIV viral load, and HIV clinical stage were unaffected by HPV-16/18 vaccine administration.
Paper Details　
Original Abstract of the Article :
In developing countries, risk of human papillomavirus (HPV) infection may be increased by the high prevalence of human immunodeficiency virus (HIV) infection. We evaluated the safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-infected women in South Africa. Asymptomatic HIV-p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2013.09.032

データ提供：米国国立医学図書館（NLM）

The HPV Vaccine in HIV-Positive Women: A Desert Oasis of Protection

In the vast desert of HIV research, where challenges are as plentiful as sand dunes, this study investigates the safety and efficacy of the HPV-16/18 vaccine in HIV-positive women. The study, conducted in South Africa, a region where both HIV and HPV prevalence are high, acts like a beacon of hope, providing important insights into the potential of this vaccine to protect women from cervical cancer. The study employed a randomized, placebo-controlled design, a rigorous approach that allowed researchers to isolate the effects of the vaccine from other factors.

A Promising Oasis: The Vaccine's Impact on Immunity

The study found that the HPV-16/18 vaccine was well-tolerated and highly immunogenic in HIV-positive women. The vaccine elicited strong antibody and T-cell responses, comparable to those observed in HIV-negative women. This finding, like a cool breeze in the desert, suggests that the vaccine can effectively stimulate the immune system even in the face of HIV infection. The study also found that the vaccine's effectiveness was not significantly influenced by the baseline CD4+ T-cell count or HIV viral load.

Hope for a Healthier Future: A Vaccine Against Cervical Cancer

This study offers a ray of hope in the fight against cervical cancer. The findings suggest that the HPV-16/18 vaccine is a safe and effective tool for protecting women with HIV from this devastating disease. This is a critical step forward in the fight against cervical cancer, particularly in regions where both HIV and HPV prevalence are high.

Dr. Camel's Conclusion

This study, like a camel carrying vital resources across the desert, provides valuable insights into the potential of the HPV vaccine to protect women with HIV from cervical cancer. The findings are a testament to the power of research to overcome challenges and improve the lives of vulnerable populations. The study serves as a reminder that even in the most challenging environments, hope and progress are possible.

Date :
  1. Date Completed 2014-06-05
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

24091311

DOI: Digital Object Identifier

10.1016/j.vaccine.2013.09.032

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.